hormone dependent neoplasms

Summary

Summary: Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.

Top Publications

  1. ncbi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
    M J Linja
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland
    Cancer Res 61:3550-5. 2001
  2. pmc A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer
    Jerome Eeckhoute
    Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 20:2513-26. 2006
  3. ncbi A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
    C W Gregory
    Laboratory for Reproductive Biology, Department of Pediatrics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Res 61:4315-9. 2001
  4. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
  5. pmc Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer
    Gang Wang
    Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer Res 68:9918-27. 2008
  6. pmc Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, United States
    Steroids 72:7-25. 2007
  7. ncbi Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Department of Medicine, Joan and Sanford I Weill College of Medicine, New York, New York 10021, USA
    Endocr Relat Cancer 11:459-76. 2004
  8. ncbi Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
    Paola Rizzo
    Breast Cancer Program and Skin Cancer Program, Cardinal Bernardin Cancer Center, Loyola University Chicago
    Cancer Res 68:5226-35. 2008
  9. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
  10. pmc Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
    P McCall
    Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK
    Br J Cancer 98:1094-101. 2008

Detail Information

Publications225 found, 100 shown here

  1. ncbi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
    M J Linja
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland
    Cancer Res 61:3550-5. 2001
    ..The two xenografts with the AR gene amplification will enable studies evaluating the functional significance of the amplification and development of new treatment strategies based on high-level expression of AR...
  2. pmc A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer
    Jerome Eeckhoute
    Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 20:2513-26. 2006
    ....
  3. ncbi A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
    C W Gregory
    Laboratory for Reproductive Biology, Department of Pediatrics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Res 61:4315-9. 2001
    ..Furthermore, we provide a molecular basis for this activation and suggest a general mechanism for recurrent prostate cancer growth...
  4. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  5. pmc Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer
    Gang Wang
    Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer Res 68:9918-27. 2008
    ..These studies provide the first in vivo evidence to support aberrant activation of the AR through the Wnt/beta-catenin signaling pathway during progression of prostate cancer to the terminal castrate-resistant stage...
  6. pmc Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, United States
    Steroids 72:7-25. 2007
    ..Current clinical trials are addressing the value of aromatase inhibitors as chemopreventive agents for postmenopausal women...
  7. ncbi Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
    Howard I Scher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Department of Medicine, Joan and Sanford I Weill College of Medicine, New York, New York 10021, USA
    Endocr Relat Cancer 11:459-76. 2004
    ..We propose that treatment regimes combining AAT with direct AR targeting strategies may provide a more complete blockade of androgen signaling, thereby preventing or significantly delaying the emergence of treatment-resistant disease...
  8. ncbi Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
    Paola Rizzo
    Breast Cancer Program and Skin Cancer Program, Cardinal Bernardin Cancer Center, Loyola University Chicago
    Cancer Res 68:5226-35. 2008
    ..Our data indicate that combinations of antiestrogens and Notch inhibitors may be effective in ERalpha(+) breast cancers and that Notch signaling is a potential therapeutic target in ERalpha(-) breast cancers...
  9. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  10. pmc Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
    P McCall
    Division of Cancer Sciences and Molecular Pathology, Glasgow Royal Infirmary, Glasgow, UK
    Br J Cancer 98:1094-101. 2008
    ....
  11. pmc A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
    Qianben Wang
    Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 27:380-92. 2007
    ..These collaborating factors, together with AR, form a regulatory hierarchy that governs androgen-dependent gene expression and prostate cancer growth and offer potential new opportunities for therapeutic intervention...
  12. ncbi Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer
    Stephane Terry
    INSERM E03 37, Universite Paris XII, Centre de Recherches Chirurgicales, Assistance Publique des Hopitaux Paris, Creteil, France
    J Cell Biochem 99:402-10. 2006
    ....
  13. ncbi Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells
    Alexandre De La Taille
    Department of Urology, Assistance Publique des Hôpitaux de Paris CHU Mondor, 94000 Creteil, France
    Clin Cancer Res 9:1801-7. 2003
    ....
  14. ncbi Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status
    Andrew G Glass
    Oncology Research, Center for Health Research, Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227, USA
    J Natl Cancer Inst 99:1152-61. 2007
    ..We examined the potential association between menopausal hormone therapy use and recent changes in breast cancer incidence...
  15. pmc Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system
    Z Culig
    Department of Urology, University of Innsbruck, Austria
    Br J Cancer 81:242-51. 1999
    ..These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention...
  16. ncbi Prostate cancer: molecular biology of early progression to androgen independence
    M D Sadar
    Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada
    Endocr Relat Cancer 6:487-502. 1999
    ..Such molecules might include small mimetic substances or agents that can gain access to the nucleus of the cell...
  17. ncbi Steroid hormone receptors in breast cancer management
    C K Osborne
    Department of Medicine, University of Texas Health Science Center at San Antonio 78284 7884, USA
    Breast Cancer Res Treat 51:227-38. 1998
    ..In summary, ER and PR status are important biomarkers that help physicians individualize therapy...
  18. ncbi Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer
    Palma Rocchi
    The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, and Division of Urology, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer Res 64:6595-602. 2004
    ..These findings suggest that increased levels of Hsp27 after androgen withdrawal provide a cytoprotective role during development of androgen independence and that ASO-induced silencing can enhance apoptosis and delay tumor progression...
  19. ncbi Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
    S Tozlu
    Centre Rene Huguenin, FNCLCC, St Cloud F 92210, France
    Endocr Relat Cancer 13:1109-20. 2006
    ..Some of the genes identified here could be useful for diagnosis or for predicting endocrine responsiveness, and could form the basis for novel therapeutic strategies...
  20. ncbi The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
    Claire Morgan
    Human Cancer Studies Group, School of Medicine, Swansea University, UK
    Acta Oncol 46:669-77. 2007
    ....
  21. ncbi The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens
    Angela H Brodie
    Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, 655 W Baltimore Street, Baltimore, MD 21201, USA
    J Steroid Biochem Mol Biol 86:283-8. 2003
    ..This suggests that resistance to letrozole may be reversible, allowing tumors to respond to subsequent antiestrogens and letrozole...
  22. pmc Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault
    J T Arnold
    National Center for Complementary and Alternative Medicine NCCAM, National Institutes of Health, 8 West Drive MSC 2669, Qtrs 15B1, Bethesda, MD 20892 2669, USA
    Endocr Relat Cancer 9:61-73. 2002
    ....
  23. ncbi Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways
    A G Latil
    Center for Research into Prostate Pathologies, Evry, France
    Cancer 92:1130-7. 2001
    ..The authors evaluated the association between polymorphisms in genes involved in the androgen biosynthesis and metabolism pathway and the risk of prostate carcinoma...
  24. pmc Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer
    Z Kolar
    Centre of Molecular Biology and Medicine, Palacky University, Olomouc, Czech
    Mol Pathol 53:15-8. 2000
    ..Recently, it has been suggested that the transition to a hormone independent state is accompanied by increased proliferation and bcl-2 gene expression, as well as by a decreased apoptotic state...
  25. ncbi Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
    ..We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response...
  26. ncbi FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas
    Karin Milde-Langosch
    Department of Gynecopathology, Institute of Pathology, University Hospital Eppendorf, Hamburg, Germany
    Breast Cancer Res Treat 77:265-75. 2003
    ....
  27. ncbi Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
    M E Taplin
    University of Massachusetts Cancer Center, Worcester 01655, USA
    Cancer Res 59:2511-5. 1999
    ..These findings demonstrate that AR mutations occur in response to strong selective pressure from flutamide treatment...
  28. pmc Estrogen as therapy for breast cancer
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 4:133-6. 2002
    ..Clinical and laboratory data together provide the basis for developing testable hypotheses of management strategies, with the potential of increasing the value of endocrine therapy in women with breast cancer...
  29. ncbi A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    Beat Thurlimann
    Senology Center of Eastern Switzerland, Kantonsspital, St Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland
    N Engl J Med 353:2747-57. 2005
    ..We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women...
  30. ncbi Hormonal carcinogenesis
    B E Henderson
    Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, MS44, PO Box 33800, Los Angeles, CA 90033 0800, USA
    Carcinogenesis 21:427-33. 2000
    ..We present data from our multi-ethnic cohort to support these models...
  31. ncbi Androgen axis in prostate cancer
    Zoran Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    J Cell Biochem 99:373-81. 2006
    ..There is experimental evidence showing that prostate tumor growth in vitro and in vivo is inhibited following administration of chemopreventive drugs or antisense oligonucleotides that downregulate AR mRNA and protein expression...
  32. ncbi Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
    Z Culig
    Department of Urology, Innsbruck Medical University, Anichstrasse 35, A 6020 Innsbruck, Austria
    Endocr Relat Cancer 12:229-44. 2005
    ..Similarly, activation of the AR by phosphorylated protein kinase B, Akt, has also been reported in prostate cancer. Activation of the Akt pathway contributes to increased survival of prostate tumour cells...
  33. ncbi Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens
    Vanessa C Thompson
    The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Prostate 66:1698-709. 2006
    ..Relaxin is a potent peptide hormone normally secreted by the prostate. This study characterized relaxin expression during prostate cancer progression to androgen independence (AI), and in response to androgens...
  34. ncbi Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice
    Lauren Wallner
    Department of Urology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 66:3087-95. 2006
    ..These data show that IL-6 contributes to the development of androgen independence in prostate cancer and suggest that it mediates this effect, in part, through modulation of p300 and CBP...
  35. ncbi A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Fred Saad
    Uro Oncology Clinic, Centre Hospitalier de l Universite de Montreal, Hopital Notre Dame, Montreal, Quebec, Canada
    J Natl Cancer Inst 94:1458-68. 2002
    ..We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on skeletal complications in prostate cancer patients with bone metastases...
  36. ncbi Aromatase inhibitors and breast cancer
    W R Miller
    Breast Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Minerva Endocrinol 31:27-46. 2006
    ..Consequently AIs offer major clinical benefits to patients with breast cancer and the promise of relatively nontoxic intervention in women at high risk of the disease...
  37. ncbi Specificity of cyclin D1 for androgen receptor regulation
    Christin E Petre-Draviam
    Department of Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0521, USA
    Cancer Res 63:4903-13. 2003
    ....
  38. ncbi Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer Res 64:9209-16. 2004
    ..An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease...
  39. doi Prostate cancer: moving forward by reinventing the wheel...but this time it is round
    Derek Raghavan
    J Clin Oncol 26:4535-6. 2008
  40. ncbi Androgen receptor signaling in androgen-refractory prostate cancer
    M E Grossmann
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    J Natl Cancer Inst 93:1687-97. 2001
    ..Identification of the role of these mechanisms in the progression to androgen-refractory prostate cancer is critical for developing therapies capable of curing this disease...
  41. ncbi Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient
    W Jonat
    Klinik fur Gynakologie und Gerburtshilfe, University of Kiel, 24105, Kiel, Germany
    J Cancer Res Clin Oncol 132:275-86. 2006
    ....
  42. ncbi [Hypoxia, HIF1alpha and estrogen receptor]
    Liliane Massaad-Massade
    Universite Rene Descartes, U 490 Inserm, 45 Rue des Saints Peres, 75270 Paris Cedex
    Bull Cancer 91:677-83. 2004
    ..The scope of this review is to summarize recent observations on these two signaling pathways and to show their importance and possible interaction in the development of hormone-dependent breast cancer...
  43. ncbi A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer
    W W He
    Department of Molecular Biology, Human Genome Sciences Inc, Rockville, Maryland 20850, USA
    Genomics 43:69-77. 1997
    ..1 is a candidate gene for playing a role in the opposing processes of androgen-driven differentiation of prostatic tissue and loss of that differentiation during the progression of prostate cancer...
  44. ncbi In vitro gene expression changes of androgen receptor coactivators after hormone deprivation in an androgen-dependent prostate cancer cell line
    Hong Chiang Chang
    Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
    J Formos Med Assoc 104:652-8. 2005
    ..This study investigated changes of expression patterns of several AR coactivators after androgen deprivation in an androgen-dependent prostate cancer cell line (LNCaP)...
  45. ncbi Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
    Stephane Oudard
    Department of Medical Oncology, Georges Pompidou European Hospital, 20 rue Leblanc, 75908, Paris Cedex 15, France
    J Clin Oncol 23:3343-51. 2005
    ..We conducted a randomized phase II study to evaluate prostate-specific antigen (PSA) response (primary end point) and safety of two docetaxel-estramustine-prednisone (DEP) regimens and mitoxantrone-prednisone (MP)...
  46. ncbi Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling
    M Soulez
    Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, UK
    J Mol Endocrinol 27:259-74. 2001
    ..Further analysis of this set of markers will provide alternative approaches to the investigation of the mitogenicity of oestrogens in breast cancer cells...
  47. ncbi Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
    Brian J Long
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Health Sciences Facility, Baltimore, MD 21201, USA
    J Natl Cancer Inst 96:456-65. 2004
    ..To determine the optimal way to use letrozole and tamoxifen, we studied their effects on a breast tumor xenograft model, MCF-7Ca, that is responsive to both antiestrogens and aromatase inhibitors...
  48. ncbi The NFkappaB pathway and endocrine-resistant breast cancer
    Y Zhou
    Buck Institute for Age Research, Novato, CA 94945, USA
    Endocr Relat Cancer 12:S37-46. 2005
    ....
  49. pmc Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function
    J S Foster
    Department of Obstetrics and Gynecology, Graduate School of Medicine, University of Tennessee Medical Center, Knoxville, Tennessee 37920, USA
    Mol Cell Biol 21:794-810. 2001
    ..These studies establish Cdc25A as a growth-promoting target of estrogen action and further indicate that estrogens independently regulate multiple components of the cell cycle machinery, including expression of p21(Cip1) and p27(Kip1)...
  50. ncbi The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation
    Gauri J Sabnis
    Department of Pharmacology and Experimental Therapeutics, University of Maryland Baltimore, Baltimore, Maryland 21201, USA
    Cancer Res 65:3903-10. 2005
    ..Cross-talk between ER and growth factor signaling was evident as inhibition of these pathways could restore estrogen responsiveness to these cells...
  51. ncbi Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones
    L J Lu
    Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston 77555 1110, USA
    Cancer Res 60:1299-305. 2000
    ....
  52. ncbi Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation
    Paramita M Ghosh
    Department of Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Endocr Relat Cancer 12:119-34. 2005
    ..Rapamycin, an mTOR inhibitor, had a growth-inhibitory effect in C4-2 cells, but not in LNCaP cells. Our data suggest a shift from a Casodex-sensitive proliferation pathway in LNCaP cells to a rapamycin-sensitive pathway in C4-2 cells...
  53. pmc Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines
    Abhik Bandyopadhyay
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Neoplasia 9:113-8. 2007
    ..Our study indicates for the first time that stable reintroduction of functional ERalpha in ERalpha-negative human breast cancer cells can inhibit their aggressive bone-metastatic potential in an experimental bone metastasis model...
  54. ncbi Aromatase and intracrinology of estrogen in hormone-dependent tumors
    N Harada
    Department of Biochemistry, Fujita Health University School of Medicine, Aichi, Japan
    Oncology 57:7-16. 1999
    ..In this context, aromatase, steroid sulfatase, estrogen sulfotransferase, and 17beta-hydroxysteroid dehydrogenases I and II are considered to be important factors in the development of hormone-dependent tumors...
  55. pmc Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression
    G B Baretton
    Institute of Pathology, Ludwig Maximilians University, Munich, Germany
    Br J Cancer 80:546-55. 1999
    ..This finding might be clinically useful for planning therapy in these patients...
  56. ncbi Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes
    Massimo Cristofanilli
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:41-8. 2005
    ..To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome...
  57. ncbi Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy
    Kate McKeage
    Adis International Limited, 41 Centorian Drive, PB 65901, Mairangi Bay, Auckland 1311, New Zealand
    Drugs 64:633-48. 2004
    ..Thus, fulvestrant provides an effective and well tolerated option for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy...
  58. ncbi Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells
    Ofelia L Zegarra-Moro
    Department of Biochemistry, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:1008-13. 2002
    ..Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens...
  59. ncbi Estrogen receptor beta in breast cancer
    C Palmieri
    Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research Campaign Laboratories, Imperial College School of Medicine, Hammersmith Campus, Du Cane Road, London W12 ONN, UK
    Endocr Relat Cancer 9:1-13. 2002
    ....
  60. ncbi Androgen receptor gene amplification and protein expression in recurrent prostate cancer
    O Harris Ford
    Department of Surgery, Division of Urology, University of North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Urol 170:1817-21. 2003
    ..AR amplification may contribute to androgen receptor activation in relative androgen absence...
  61. ncbi Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    Alan S Coates
    International Breast Cancer Study Group IBCSG, IBCSG Coordinating Center, Bern, Switzerland
    J Clin Oncol 25:486-92. 2007
    ..Because this presentation may unduly reflect early events, the present analysis is limited to patients randomly assigned to the continuous therapy arms and includes protocol-defined updated results...
  62. ncbi Pharmacokinetics of third-generation aromatase inhibitors
    Per Lønning
    Department of Therapeutic Oncology and Radiophysics, Haukeland Hospital, University of Bergen, Bergen, Norway 5021
    Semin Oncol 30:23-32. 2003
    ..However, the significance of these differences for clinical effectiveness over long-term use remains to be determined...
  63. ncbi Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression
    Sophie F Doisneau-Sixou
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, Australia
    Int J Cancer 106:789-98. 2003
    ..Together, these results suggest that the combination of FTI and tamoxifen may increase the antitumor effect of either drug alone in breast cancer...
  64. ncbi Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells
    Anne Marie Carey
    King s College London, Rayne Institute, London, United Kingdom
    Int J Cancer 121:520-7. 2007
    ....
  65. ncbi Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells
    Pao F Kue
    Department of Surgery Urology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 102:572-9. 2002
    ..Together, our data show that LPA and EGF cooperate to induce mitogenic signaling in prostate cancer cells in an MMP-regulated activation of the ERK pathway...
  66. ncbi Development of cDNA microarray for expression profiling of estrogen-responsive genes
    A Inoue
    Division of Endocrinology, Saitama Cancer Center Research Institute, 818 Komuro, Ina machi, Kitaadachi gun, Saitama ken 362 0806, Japan
    J Mol Endocrinol 29:175-92. 2002
    ..Several genes also showed up-regulation or down-regulation by estrogen in cell lines other than MCF-7 cells. The significance of the estrogen-responsive genes identified in these analyses concerning the nature of cancer is discussed...
  67. ncbi Adjuvant hormonal therapy for premenopausal women with breast cancer
    Leisha A Emens
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 9:486S-94S. 2003
    ....
  68. pmc ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Breast Cancer Res 10:R76. 2008
    ..Of particular interest is their oestrogen-receptor (ER) status because endocrine adjuvant therapy remains a cornerstone of breast cancer treatment...
  69. ncbi Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line
    Clifford G Tepper
    Division of Basic Sciences, University of California Davis Cancer Center and Department of Biological Chemistry, University of California, Davis School of Medicine, Sacramento, California 95817, USA
    Cancer Res 62:6606-14. 2002
    ..In summary, the CWR22Rv1 cell line displays both androgen-responsive and androgen-insensitive features due, at least in part, to a novel insertional mutation of the AR...
  70. ncbi Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations
    R E Coleman
    Academic Unit of Clinical Oncology, Weston Park Hospital, Witham Road, Sheffield S10 2SJ, UK
    Cancer Treat Rev 34:275-82. 2008
    ..Knowing that joint symptoms can be managed in most patients may encourage patient-physician communication and treatment compliance...
  71. ncbi Beta-catenin signaling in prostate cancer: an early perspective
    D R Chesire
    Brady Urological Institute Research Laboratories, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Endocr Relat Cancer 10:537-60. 2003
    ....
  72. ncbi Adjuvant endocrine therapy
    Lars E Rutqvist
    Karolinska Institute and Huddinge University Hospital, Sodersjukhuset, SE 181 86 Stockholm, Sweden
    Best Pract Res Clin Endocrinol Metab 18:81-95. 2004
    ....
  73. ncbi Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect
    Matthew J Ellis
    Breast Cancer Program, DUMC, Duke University, PO Box 3446, Durham, NC 27710, USA
    J Steroid Biochem Mol Biol 86:301-7. 2003
    ..When enough profiles have been generated it should be possible to detect complex interaction patterns that correctly reclassify ER+ disease into treatment responsive and resistant categories with high probability...
  74. ncbi Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria
    Jin Qiang Chen
    Division of Pulmonary and Critical Care, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908 0546, USA
    Adv Exp Med Biol 630:1-18. 2008
    ....
  75. ncbi Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
    L Mauriac
    French Breast Cancer Group, Institut Bergonié Bordeaux, France
    Ann Oncol 18:859-67. 2007
    ..Awaiting results from ongoing randomized trials, we examined prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices...
  76. ncbi Role of the androgen receptor axis in prostate cancer
    Zoran Culig
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Urology 62:21-6. 2003
    ..It is hoped that continuing research on AR expression and function in prostate cancer will pave the way for new therapeutic strategies...
  77. ncbi Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens
    Angela Brodie
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21202 1559, USA
    Clin Cancer Res 9:455S-9S. 2003
    ..These results demonstrate that this aromatase inhibitor is more effective and has a longer duration of response as a single agent than tamoxifen or in combination with tamoxifen...
  78. ncbi Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial
    Luigi Cataliotti
    Clinica Chirurgica 1, University degli Studi di Firenze, Firenze, Italy
    Cancer 106:2095-103. 2006
    ..The effect of preoperative endocrine therapy in patients scheduled for mastectomy or with inoperable tumors at baseline was also investigated...
  79. ncbi Adiponectin as a negative regulator in obesity-related mammary carcinogenesis
    Yu Wang
    Genome Research Center, University of Hong Kong, Hong Kong SAR, China
    Cell Res 17:280-2. 2007
  80. ncbi Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health
    Fabrice Journe
    Universite Libre de Bruxelles ULB, Laboratory of Endocrinology and Bone Diseases, Institut Jules Bordet, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Expert Opin Drug Saf 7:241-58. 2008
    ..We conclude that, because of its therapeutic efficacy and its seemingly minimal effect on bone integrity, fulvestrant represents a new option for the hormonal treatment of breast cancer that deserves further clinical evaluation...
  81. ncbi Aromatase inhibitors--a triumph of translational oncology
    Sandra M Swain
    N Engl J Med 353:2807-9. 2005
  82. ncbi Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells
    M H Jeng
    Department of Internal Medicine, University of Virginia Health System, Charlottesville, USA
    Breast Cancer Res Treat 62:167-75. 2000
    ..Taken together, our data suggest that the MAP kinase pathway is, in part, involved in the adaptive process which results in enhanced DNA synthesis and cell proliferation in the absence of exogenous estrogen in LTED cells...
  83. ncbi Local endocrine effects of aromatase inhibitors within the breast
    W R Miller
    Breast Unit, Department of Clinical Oncology, Western General Hospital, University of Edinburgh, Crewe Road South, EH4 2XU, Edinburgh, UK
    J Steroid Biochem Mol Biol 79:93-102. 2001
    ....
  84. ncbi Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells
    Elizabeth M Bruckheimer
    J Urol 169:1553-7. 2003
    ..This observation suggests that the expression of bcl-2 may be negatively regulated by androgens in prostate cancer cells...
  85. ncbi Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice
    Young H Ju
    Department of Food Science and Human Nutrition, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    Cancer Res 62:2474-7. 2002
    ..g., pS2, PR, and cyclin D1). Therefore, caution is warranted for postmenopausal women consuming dietary genistein while on TAM therapy for E-responsive breast cancer...
  86. ncbi Letrozole after tamoxifen for breast cancer--what is the price of success?
    John Bryant
    N Engl J Med 349:1855-7. 2003
  87. ncbi [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate]
    Antonio Berenguer Sanchez
    Arch Esp Urol 55:771-5. 2002
  88. ncbi Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer
    Jens Hoffmann
    Research Laboratories of Schering AG, Berlin, Germany
    J Natl Cancer Inst 96:210-8. 2004
    ..We characterized two new pure antiestrogens-ZK-703 and ZK-253-that belong to the class of specific estrogen receptor destabilizers (SERDs), which includes fulvestrant, and compared their activity with that of fulvestrant and tamoxifen...
  89. pmc The discovery and mechanism of action of letrozole
    Ajay S Bhatnagar
    World Wide Services Group Ltd, Geispelgasse 13, CH 4132, Muttenz, Switzerland
    Breast Cancer Res Treat 105:7-17. 2007
    ..An extensive program of randomized clinical trials has demonstrated the clinical benefits of letrozole across the spectrum of hormone-responsive breast cancer in postmenopausal women...
  90. ncbi The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics
    Clay E S Comstock
    Department of Cell and Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    Cell Cycle 6:1307-13. 2007
    ....
  91. ncbi Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition
    J Spicer
    Department of Medical Oncology, Academic Oncology Offices, 3rd Floor, Thomas Guy House, Guy s and St Thomas Hospital, St Thomas Street, London, UK
    Cancer Lett 248:165-74. 2007
    ..Comparison is made between initial aromatase inhibition, switching, and extended adjuvant strategies. Practical recommendations are given for the endocrine treatment of post-menopausal breast cancer...
  92. pmc Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer
    W R Miller
    Breast Unit, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Br J Cancer 87:950-5. 2002
    ....
  93. ncbi Anti-tumor effects of letrozole
    W R Miller
    Breast Unit Research Group, University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK
    Cancer Invest 20:15-21. 2002
    ..Letrozole is a drug of immense potential and in the future is likely to occupy a central role in the management of postmenopausal women with hormone-dependent breast cancer...
  94. ncbi Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer
    K Suzuki
    Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Science, Asahimachi 1 757, Niigata 951 8510, Japan
    Prostate Cancer Prostatic Dis 10:301-6. 2007
    ..This is the first report confirming this mechanism experimentally and also suggest the use of combined therapies that target ARs and prevent the formation of DHT within prostate cancer cells to achieve optimal therapeutic efficacy...
  95. ncbi Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins
    Ramneet Kaur
    Department of Medicine, Cancer Biology Program, Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Prostate 68:1510-6. 2008
    ....
  96. ncbi EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity
    Ming Lu
    Department of Basic Medical Sciences, Purdue University Cancer Center, West Lafayette, Indiana 47907, USA
    Cancer Res 63:3425-9. 2003
    ..These results have important implications for understanding the molecular basis underlying estrogen dependence and provide further evidence that EphA2 may provide a much-needed therapeutic target for breast cancer...
  97. ncbi mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen
    Francoise Revillion
    Laboratoire d Oncologie Moléculaire Humaine, Centre Oscar Lambret, 3 Rue Frederic Combemale, BP 309, 59020 Lille, France
    Anticancer Res 23:1455-60. 2003
    ..In the present paper, we simultaneously quantified, for the first time, the mRNA expression of these four receptors in response to estradiol and 4-hydroxy-tamoxifen in the prototypical ER-positive human breast cancer cell line MCF-7...
  98. pmc Letrozole in the neoadjuvant setting: the P024 trial
    Matthew J Ellis
    Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:33-43. 2007
    ..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer...
  99. pmc Letrozole in the extended adjuvant setting: MA.17
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Cox Bldg, Room 640, Boston, MA 02114, USA
    Breast Cancer Res Treat 105:45-53. 2007
    ....
  100. ncbi A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1084-9. 2008
    ..To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites..
  101. ncbi Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
    J N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 19:877-82. 2008
    ..57, P = 0.00008]. The trial was unblinded and placebo patients were offered letrozole...

Research Grants71

  1. DETERMINANTS OF TISSUE ESTRADIOL SENSITIVITY
    Richard Santen; Fiscal Year: 2009
    ..FTS, a novel mTOR inhibitor will be used in vitro to activate the stress kinase pathway and apoptosis. In vivo, FTS will be used to enhance estradiol induced apoptosis in nude mice. ..
  2. ROLE OF THE CELL CYCLE IN HYPERSENSITIVITY TO ESTRADIOL
    Richard Santen; Fiscal Year: 2008
    ..A clinical trial in women, which is designed to specifically demonstrate that high dose estrogen induces tumor regression through the mechanism of apoptosis will be conducted. ..
  3. ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
    Angela Brodie; Fiscal Year: 2008
    ..Determine effective doses, scheduling, and route of administration and b. Compare the effect of lead inhibitors and castration on apoptosis to identify the best compound. ..
  4. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
    ..In addition, this project will provide important insights into the relative contributions of testosterone and estrogen in bone metabolism, and maintenance of muscle size and strength in older men. ..
  5. ESTROGEN BIOTRANSFORMATIONS AND BREAST CANCER ETIOLOGY
    ROBERT BRUEGGEMEIER; Fiscal Year: 2006
    ..3) To measure cellular levels of aromatase expression and cyclooxygenases expression in human breast cancer specimens. ..
  6. PERINATAL ESTROGEN, OXIDATIVE DAMAGES & UTERINE LESIONS
    Deodutta Roy; Fiscal Year: 2005
    ....
  7. Treatment of Older Patients with Early Breast Cancer
    Arash Naeim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  8. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  9. c-erbB-2 and Risk of Contralateral Breast Cancer
    Christopher Li; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  10. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  11. Pharmacogenetics of Sulfate Conjugation
    VIRGIL JORDAN; Fiscal Year: 2006
    ..These results will increase our understanding of the contribution of SULT1A1 pharmacogenetics to individual variation in response to estrogens and an important antiestrogen. ..
  12. Biomarker modulation/COX-2 inhibitor/Breast Cancer
    Banu Arun; Fiscal Year: 2003
    ..Ultimately, the development of non-hormonal chemoprevention agents, and identification of surrogate markers will allow us to plan large-scale, phase III chemoprevention studies with the endpoint of cancer incidence. ..
  13. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  14. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  15. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  16. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2009
    ..such as parity and body mass index, modify this association?;and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  17. EFFECT OF RALOXIFENE ON SALIVARY STEROIDS
    VIRGIL JORDAN; Fiscal Year: 2002
    ..Most importantly, completion of the study will validate an important new methodology to monitor the ovarian effects of any new chemopreventive that can be used in premenopausal women. ..
  18. First International Inflammatory Breast Cancer Conference
    Massimo Cristofanilli; Fiscal Year: 2008
    ..For project details please see "Conference Plan". [unreadable] [unreadable] [unreadable]..
  19. COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM
    Daniel Petrylak; Fiscal Year: 2003
    ..Based on substantial laboratory strength, we intend to integrate Columbia laboratory resources as core support for SWOG clinical studies. ..
  20. NONHISTONE PROTEINS AND HORMONAL CARCINOGENESIS
    Deodutta Roy; Fiscal Year: 2001
    ....
  21. Correlative Studies of erbB-2/HER2 and p53 in CALGB Pro.
    Daniel Hayes; Fiscal Year: 2005
    ....
  22. 5th International Symposium on Hormonal Carcinogenesis
    Jonathan Li; Fiscal Year: 2006
    ..Area 4: Hormone Dependency and Independency. e) In prostate, breast and uterine cancer, Session 6. As in the past, a book will be published of the presentations. [unreadable] [unreadable] [unreadable] [unreadable]..
  23. GnRH Agonists For Prostate Cancer: Role of the Urologist
    Vahakn Shahinian; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  24. Mechanisms of Growth Factor-Estrogen Receptor Crosstalk
    Stephen Safe; Fiscal Year: 2006
    ..abstract_text> ..
  25. Genomic Instability and Etiology of Estrogen Oncogenesis
    Jonathan Li; Fiscal Year: 2007
    ..abstract_text> ..
  26. FlaxSeed Lignan for Breast Cancer Chemoprevention
    CAROL FABIAN; Fiscal Year: 2007
    ..If positive, the results of this study will be critical to the design and implementation of a placebo-controlled Phase II prevention trial with Brevail and/or commercial flaxseed. [unreadable] [unreadable]..
  27. Coregulators in Androgen-Refractory Prostate Cancer
    Donald J Tindall; Fiscal Year: 2010
    ..These studies should enhance our understanding of the mechanisms involved in androgen refractory PCa, and may lead to the identification of new therapeutic targets. ..
  28. Biochemical markers of bone turnover in metastatic prostate cancer
    Primo N Lara; Fiscal Year: 2010
    ....
  29. Vitamin D and Mammographic Density
    Rulla Tamimi; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  30. Androgen and Growth Factor Signaling in Prostate Cancer
    Michael Weber; Fiscal Year: 2008
    ..This research will be informative with respect to understanding the integration of steroid and growth factor signaling, as well as in identifying the optimal therapeutic targets for advanced prostate cancer. ..
  31. Breast Cancer Risk Biomarkers and Energy Balance
    CAROL FABIAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  32. Androgen and Wnt Beta-catenin Signaling Pathways in Prostate Cancer
    Zijie Sun; Fiscal Year: 2008
    ..abstract_text> ..
  33. Modeling ovarian carcinoma by defined genetic alterations
    Alexander Nikitin; Fiscal Year: 2009
    ..abstract_text> ..
  34. Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
    Timothy Lash; Fiscal Year: 2009
    ..Understanding the modification of tamoxifen effectiveness by genetic polymorphisms or drug interactions will help patients and physicians to make fully informed decisions about hormone therapy. ..
  35. TOXICOLOGY OF ENVIRONMENT CONTAMINANTS
    Stephen Safe; Fiscal Year: 2007
    ..The proposed training program will continue to provide trainees with a challenging academic and research environment that will prepare them for future careers in academic, industry and government. ..
  36. STUDIES OF NORMAL AND NEOPLASTIC PROSTATE
    Khalil Ahmed; Fiscal Year: 2008
    ..The relevance of these studies is underscored by the fact that prostate cancer is a leading cause of cancer-related deaths in men in the U.S.A. ..
  37. Breast Cancer Prevention by Letrozole in High Risk Women
    Carol J Fabian; Fiscal Year: 2010
    ....
  38. AMINO ACID CONJUGATION OF BILE ACIDS
    Stephen Barnes; Fiscal Year: 2006
    ..abstract_text> ..
  39. Androgenic Inactivation of FKHR in Prostate Cancer
    Donald Tindall; Fiscal Year: 2006
    ..Also, identification of such novel proteins will enable us to better manipulate androgen-regulated events in BPH and prostate cancer. ..
  40. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  41. AREA-BASED SOCIOECONOMIC MEASURES FOR HEALTH DATA
    Nancy Krieger; Fiscal Year: 2003
    ....
  42. Enhancing the Safety of Research Participants
    Donald Trump; Fiscal Year: 2003
    ..abstract_text> ..
  43. SMOKING & GENETIC INTERACTION IN BREAST CANCER ETIOLOGY
    Timothy Lash; Fiscal Year: 2004
    ..The second study would collect buccal swabs from participants in the study of adjuvant tamoxifen therapy (Dr. Silliman PI). A similar analytic plan would be conducted, but with a case-only design. ..
  44. 4th International Symposium on Hormonal Carcinogenesis
    Jonathan Li; Fiscal Year: 2003
    ..abstract_text> ..
  45. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2003
    ....
  46. Inhibition of Androgen Receptor Activation
    Robert Fletterick; Fiscal Year: 2003
    ..Our experiments will thus provide a distinct pathway for inhibiting androgen receptor sensitive tumor and metastatic cell growth. ..
  47. PROTEASE SPECIFICITY AND INHIBITION
    Robert Fletterick; Fiscal Year: 2002
    ....
  48. NORMAL AND NEOPLASTIC PROSTATE
    Khalil Ahmed; Fiscal Year: 2002
    ..In summary, these studies will provide fundamentally important new information on the mechanisms of CK2 functional activity as well as its implications in prostate tumor biology and a potential therapeutic target. ..
  49. 9.4 Tesla Fourier Transform Mass Spectrometer
    Stephen Barnes; Fiscal Year: 2002
    ..Overall, the FT-MS instrument will sustain the high quality of biomedical research that is a hallmark of UAB. ..
  50. COMMON VARIANTS IN CANDIDATE GENES AND PREMATURE MI RISK
    Stephen Schwartz; Fiscal Year: 2001
    ....
  51. PHENYLACETATE--NOVEL THERAPEUTIC USES IN BREAST CANCER
    Neil Sidell; Fiscal Year: 2005
    ..Taken together, the information gained from these studies will provide a basic framework for the rationale use of PA analogs or similar acting compounds in the clinic. ..
  52. NOVEL MARKERS FOR PROSTATE CANCER
    Charles Young; Fiscal Year: 2005
    ..He will develop highly sensitive and specific immunoassays for PSA-v in order to enhance the performance of current PSA tests and to reduce the number of unnecessary biopsies. ..
  53. Chemoprevention of Bladder CA by soybean bioactive comp.
    Jin Rong Zhou; Fiscal Year: 2006
    ..abstract_text> ..
  54. ALKYL PCDFS--INHIBITION OF MAMMARY CANCER
    Stephen Safe; Fiscal Year: 2001
    ..Thus the proposed studies will define a new mechanism-based class of antiestrogens that can be used alone or in combination with tamoxifen for treatment of breast and endometrial cancer. ..
  55. Crystal Farm Imaging System
    Robert Fletterick; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  56. Coactivation of Estrogen Receptor alpha/Sp1
    Stephen Safe; Fiscal Year: 2006
    ..abstract_text> ..
  57. TUMT verses Medical Therapy in Treatment of BPH
    E Crawford; Fiscal Year: 2005
    ..The PI has enlisted the support of consultants who will assist in this important evaluation. The results of this analysis will be critical in allocating health care resources. ..
  58. STEM CELL-BRAIN TUMOR INTERPLAY & IN VIVO PHAGE DISPLAY
    Wadih Arap; Fiscal Year: 2005
    ..abstract_text> ..
  59. Socioeconomic Trends in Breast Cancer Incidence
    Nancy Krieger; Fiscal Year: 2005
    ..Results of this investigation will provide new insights into social determinants of and secular changes in breast cancer incidence, with implications for breast cancer surveillance, screening and control. ..
  60. Physical Activity, Aging and Immune Function
    Jeffrey Woods; Fiscal Year: 2005
    ..In addition, the biobehavioral approach inherent in our aims will allow us to determine the complexity of the relationship between exercise and immune function. ..
  61. ETIOLOGIC HETEROGENEITY IN LATE ONSET BREAST CANCER
    Timothy Rebbeck; Fiscal Year: 2001
    ..The results of these analyses will be used to attempt to elucidate the complex, multifactorial aetiology of late onset breast cancer. ..
  62. Support of the Caregiver of the Older Cancer Patient Undergoing Chemotherapy
    Lodovico Balducci; Fiscal Year: 2008
    ..This study provides an opportunity to address problems associatedwith intense short-term caregiving in this expanding population. ..
  63. Lipitor/Celebrex: effect on prostate cancer progression
    Xi Zheng; Fiscal Year: 2007
    ..This combination of drugs may significantly improve the management of prostate cancer. [unreadable] [unreadable] [unreadable]..
  64. Ethnic difference in prostate cancer
    Timothy R Rebbeck; Fiscal Year: 2010
    ....
  65. Optimizing use of androgen deprivation therapy for prostate cancer
    Vahakn B Shahinian; Fiscal Year: 2010
    ..POP dominant) on care of men on ADT. ..
  66. REGULATION OF GENES BY T AND DHT IN RAT AND HUMAN PROSTA
    Michael McPhaul; Fiscal Year: 2001
    ..The results of these studies will help define the distinct roles that T and DHT play in androgen physiology and indicate the directions that efforts to selectively interfere with the actions of T and DHT can take. ..
  67. Imaging Tumor Blood Vessels in Bone Metastases from Breast Cancer
    Wadih Arap; Fiscal Year: 2006
    ..In addition, probes that target breast cancer vasculature will be developed as delivery tools and will likely enhance effectiveness of current imaging technology. ..
  68. Molecular Diversity in Bladder Cancer
    Wadih Arap; Fiscal Year: 2009
    ..Herein we propose to pursue candidate peptides with the ability to internalize into urothelial cells to develop therapeutic targeting strategies for the treatment of bladder cancer. ..
  69. Prevention of Osteoporosis in Men with Prostate Cancer
    Susan Greenspan; Fiscal Year: 2005
    ..This study will examine a preventive strategy, the potential mechanism of bone loss, the ability of biochemical marker to predict bone mass, and skeletal outcomes when antiresorptive therapy is withdrawn. ..
  70. The impact of androgen ablation therapy on cognition in*
    Christian Nelson; Fiscal Year: 2006
    ..2. To determine the severity of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years. ..